Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 2/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.49 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7205749 | 0.91 | PDE4D (0.57) | PDE4DMAPK1LMNAHTTTSHR | |
| SCHEMBL4176914 | 0.89 | PDE4D (0.61) | PDE4DMAPK1HTTTSHRPOLB | |
| SCHEMBL29306680 | 0.85 | PDE4D (0.52) | PDE4DMAPK1LMNAHTTTSHR | |
| SCHEMBL7204680 | 0.84 | TSHR (0.58) | PDE4DMAPK1HTTTSHRPOLB | |
| SCHEMBL4187978 | 0.84 | PDE4D (0.54) | PDE4DMAPK1HTTTSHRPOLB | |
| SCHEMBL7204752 | 0.83 | PDE4D (0.61) | PDE4DMAPK1LMNAHTTTSHR | |
| SCHEMBL4194071 | 0.82 | PDE4D (0.58) | PDE4DMAPK1LMNAHTTTSHR | |
| SCHEMBL2789661 | 0.82 | SERPINE1 (0.63) | PDE4DMAPK1LMNAHTTTSHR | |
| SCHEMBL4190701 | 0.81 | PDE4D (0.54) | PDE4DMAPK1HTTTSHRPOLB | |
| SCHEMBL4184692 | 0.81 | PDE4D (0.54) | PDE4DMAPK1LMNAHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1045690-B1 | BENZENESULFONAMIDE INHIBITORS OF PDE-IV AND THEIR THERAPEUTIC USE | WARNER LAMBERT CO (US) | 2003-04-23 | — | — | EP | claimed |
| US-6162830-A | Benzenesulfonamide inhibitors of PDE-IV and their therapeutic use | WARNER-LAMBERT COMPANY (US) | 2000-12-19 | — | — | US | claimed |
| EP-1045690-A1 | BENZENESULFONAMIDE INHIBITORS OF PDE-IV AND THEIR THERAPEUTIC USE | WARNER-LAMBERT COMPANY (US) | 2000-10-25 | — | — | EP | claimed |
| WO-1999026616-A1 | BENZENESULFONAMIDE INHIBITORS OF PDE-IV AND THEIR THERAPEUTIC USE | WARNER-LAMBERT COMPANY (US) | 1999-06-03 | — | — | WO | claimed |
| US-20230125270-A1 | RADIATION SENSITIVE COMPOSITION | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20180181000-A1 | RADIATION SENSITIVE COMPOSITION | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-06-28 | — | — | US | disclosed |
| EP-1045690-B1 | BENZENESULFONAMIDE INHIBITORS OF PDE-IV AND THEIR THERAPEUTIC USE | WARNER LAMBERT CO (US) | 2003-04-23 | — | — | EP | disclosed |
| US-6162830-A | Benzenesulfonamide inhibitors of PDE-IV and their therapeutic use | WARNER-LAMBERT COMPANY (US) | 2000-12-19 | — | — | US | disclosed |
| EP-1045690-A1 | BENZENESULFONAMIDE INHIBITORS OF PDE-IV AND THEIR THERAPEUTIC USE | WARNER-LAMBERT COMPANY (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999026616-A1 | BENZENESULFONAMIDE INHIBITORS OF PDE-IV AND THEIR THERAPEUTIC USE | WARNER-LAMBERT COMPANY (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180181000-A1 | RADIATION SENSITIVE COMPOSITION | RER1, RAD1, RAD51 | PDE4D 3610/4885MAPK1 2769/4885LMNA 247/4885 |
| US-20230125270-A1 | RADIATION SENSITIVE COMPOSITION | XRCC6, RAD50, XRCC5 | PDE4D 4237/4885MAPK1 1253/4885LMNA 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.